The future of nanomedicines in oncology requires leveraging more than just the passive drug accumulation in tumors through the enhanced permeability and retention effect. Promising results combining mild hyperthermia (HT) with lyso-thermosensitive liposomal doxorubicin (LTSL-DOX) has led to improved drug delivery and potent antitumor effects in pre-clinical studies. The ultimate patient benefit from these treatments can only be realized when robust methods of HT can be achieved clinically. One of the most promising methods of non-invasive HT is the use of focused ultrasound (FUS) with MRI thermometry for anatomical targeting and feedback. MRI-guided focused ultrasound (MRgFUS) is limited by respiratory motion and large blood vessel cooling. In order to translate exciting pre-clinical results to the clinic, novel heating approaches capable of overcoming the limitations on clinical MRgFUS+HT must be tested and evaluated on their ability to locally release drug from LTSL-DOX.

中文翻译：

---

使用热敏脂质体的聚焦超声热疗介导的药物递送，并通过体内双光子显微镜可视化

肿瘤学中纳米药物的未来需要通过增强的通透性和保留效应来利用更多的信息，而不只是利用被动药物在肿瘤中的蓄积。在临床前研究中，将轻度高温（HT）与溶酶热敏感性脂质体阿霉素（LTSL-DOX）结合的令人鼓舞的结果已导致改善的药物递送和有效的抗肿瘤作用。只有在临床上可以实现可靠的HT方法时，才能从这些治疗中获得最终的患者利益。非侵入性HT最有前途的方法之一是将聚焦超声（FUS）与MRI测温法一起用于解剖学靶向和反馈。MRI引导的聚焦超声（MRgFUS）受呼吸运动和大血管冷却的限制。为了将令人兴奋的临床前结果转化为临床结果，